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Abstract 
The motor axonal variant of Guillain-Barré syndrome is associated with anti-
GD1a IgG antibodies which are believed to be the pathogenic factor. In previous 
studies we have demonstrated the motor terminal to be a vulnerable site. Here 
we show both in vivo and ex vivo that nodes of Ranvier in intramuscular motor 
nerve bundles are also targeted by anti-GD1a antibody in a gradient-dependent 
manner, with greatest vulnerability at distal nodes. Complement deposition is 
associated with prominent nodal injury as monitored with electrophysiological 
recordings and fluorescence microscopy. Complete loss of nodal protein staining, 
including voltage-gated sodium channels and ankyrin G, occurs and is 
completely protected by both complement and calpain inhibition, although the 
latter provides no protection against electrophysiological dysfunction. In ex vivo 
motor and sensory nerve trunk preparations, antibody deposits are only observed 
in experimentally desheathed nerves, which are thereby rendered susceptible to 
complement-dependent morphological disruption, nodal protein loss and reduced 
electrical activity of the axon. These studies provide a detailed mechanism by 
which loss of axonal conduction can occur in a distal dominant pattern as 
observed in a proportion of motor axonal Guillain-Barré syndrome patients, and 
also provide an explanation for the occurrence of rapid recovery from complete 
paralysis and electrophysiological in-excitability. The studies also identify 
therapeutic approaches in which nodal architecture can be preserved.  
 
Keywords: Anti-GD1a antibody, GD1a ganglioside, node of Ranvier, acute motor 
axonal neuropathy, complement, calpain. 
 Abbreviations: α-BTx, α-bungarotoxin; AMAN, acute motor axonal neuropathy; 
BNB, blood nerve barrier; CAP, compound action potential; CFP, cyan 
fluorescent protein, CFP; GBS, Guillain-Barré syndrome; GD3s, GD3 synthase; 
LOS, lipo-oligosaccharides; LTx, alpha-latrotoxin; mAb, monoclonal antibody; 
MAC, membrane attack complex; NF, neurofilament; NHS, normal human serum, 
NoR; node of Ranvier; PBS, phosphate-buffered saline; TTx, tetrodotoxin; TS, 
triangularis sternae; RT, room temperature; WT, wild type. 
Introduction 
 
The motor axonal variant of Guillain-Barré syndrome (GBS), termed acute motor 
axonal neuropathy (AMAN) (Feasby et al., 1986;Hughes and Cornblath 
2005;McKhann et al., 1993) characteristically follows Campylobacter jejuni 
infection and is associated with serum anti-GM1, -GD1a and -GalNAc-GD1a 
ganglioside antibodies (Ho et al., 1999;Lugaresi et al., 1997;Ogawara et al., 
2000). AMAN-associated Campylobacter jejuni strains have ganglioside-like 
surface lipo-oligosaccharides (LOS) Aspinall et al., 1993) suggesting induction is 
due to a mechanism of molecular mimicry, which has been proven 
experimentally (Ang et al., 2004;Goodyear et al., 1999). 
Gangliosides are sialic acid-containing glycosphingolipids expressed at 
high levels in the nervous system in a range of cell-specific patterns (Ledeen 
1978). Gangliosides have diverse functions related to neural development, 
maintenance and regeneration, including stabilising the axo-glial junction at the 
node of Ranvier (NoR) (Sheikh et al., 1999b;Susuki et al., 2007a;Silajdzic et al., 
2009). Although no specific neural function has been attributed to GD1a, it has 
been identified in the motor nerve terminal and nodal axolemma (De Angelis et 
al., 2001;Gong et al., 2002;Goodfellow et al., 2005;Sheikh et al., 1999a), sites 
which correspond to those predicted from clinical, electrophysiological and 
pathological data to be affected in motor axonal forms of GBS (Griffin et al., 
1996;Ho et al., 1997;Kuwabara et al., 2004).  
The distal motor nerve, nerve terminal and ventral roots have relatively 
higher permeability to circulating factors than nerve trunks, owing to local 
variations in the protective properties of the blood nerve barrier (BNB) (Burkel 
1967;Malmgren and Olsson 1980;Olsson 1990;Saito and Zacks 1969). These 
BNB variations could allow circulating antibody access to either very distal or 
very proximal motor axonal membranes and thereby account for more targeted 
injury to these regions. Thus it has been proposed that one explanation for the 
very rapid recovery from paralysis seen in some AMAN patients could be due to 
axonal conduction block at the distal motor axon and nerve terminal, a site with 
the capacity to regenerate rapidly (Goodfellow et al., 2005;Ho et al.,1997). 
Conversely, severe proximal axonal injury resulting in widespread axonal 
degeneration that overwhelmed the compensatory capacity of motor unit 
remodelling would inevitably lead to permanent motor axonal deficits, as is seen 
in some AMAN cases (Hiraga et al., 2005a;Hiraga et al., 2005b). 
Several anti-GM1 and -GD1a ganglioside antibody-mediated mouse and 
rabbit models of AMAN have been generated (Goodfellow et al., 2005;Sheikh et 
al., 2004;Susuki et al., 2003). Models to date have focused on sciatic nerve and 
ventral root axons, or on axonal components of neuromuscular junctions. In a 
passive immunisation mouse model of AMAN mediated by anti-GD1a antibody 
supplemented with guinea pig complement, axonal injury was observed in spinal 
roots and sciatic nerve (Sheikh et al., 2004). Similarly in a rabbit model induced 
by active immunisation with GM1, axonal injury was observed in spinal roots, in 
which rabbit complement deposits were also evident (Susuki et al., 2003). 
Extensions of this study focussing on the NoR revealed destabilisation of nodal 
and paranodal structures, including loss of sodium (NaV) channels, findings 
interpreted as the consequence of antibody and complement-mediated axo-glial 
disruption(Susuki et al., 2007b), and their protection with a complement inhibitor 
(Phongsisay et al., 2008).  
These complement mediated effects at the NoR in the ventral root mirror 
those demonstrated in patient autopsy tissue (Hafer-Macko et al., 1996). As the 
NoR is vital for impulse propagation (Poliak and Peles 2003;Scherer 1996), 
understanding AMAN immunopathology at this site in relation to function is both 
critical and complex. The NoR is organised into 3 subdomains - the nodal gap, 
the paranode and the juxtaparanode (Fig. S8). The voltage-gated sodium 
channel isoform Nav1.6 is expressed at the NoR (Caldwell et al., 2000), along 
with the cytoskeletal protein ankyrin G (Kordeli et al., 1990) and the cell adhesion 
molecules neurofascin 186 and NrCAM (Davis et al., 1996). At the paranode, the 
axo-glial junction is formed by the axolemmal proteins contactin and Caspr, while 
neurofascin 155 is the glial receptor to this complex (Charles et al., 
2002;Einheber et al., 1997;Menegoz et al., 1997;Peles et al., 1997;Rios et al., 
2000;Tait et al., 2000). The axo-glial junction acts as a barrier to prevent lateral 
movement of nodal constituents, thus organising the channel clustering required 
for maintenance of membrane potentials (Bhat et al., 2001;Boyle et al., 2001). At 
the juxtaparanode, voltage-gated potassium channels localised on the axon, in 
complex with Caspr 2 and Tag1 (Arroyo et al., 1999;Wang et al., 1993), play a 
role in repolarisation the resting membrane potential following an action potential 
(Poliak and Peles2003;Rasband et al., 2002;Traka et al., 2002). 
Glycosyltransferase knockout mouse studies indicate that GD1a or related 
gangliosides clearly modulate the structural and functional integrity of this site, 
although the precise mechanisms are poorly understood (Sheikh et 
al.,1999b;Silajdzic et al., 2009;Susuki et al., 2007a). 
In our ex vivo mouse model of AMAN, motor nerve terminals enriched in 
GD1a develop severe functional and pathological injury when exposed to anti-
GD1a antibody with complement activation(Goodfellow et al., 2005). The pore 
forming action of complement is critical to the development of this injury and that 
mediated by other anti-ganglioside antibodies, in part through allowing 
uncontrolled calcium influx into the nerve terminals, with subsequent Ca2+-
dependent protease, calpain, activation and cleavage of structural proteins in the 
axon terminal (O'Hanlon et al., 2003).  
This study set out to assess whether anti-GD1a-antibody mediated injury 
could be observed to occur at NoR in the distal portions of the axon, upstream 
from the motor nerve terminal. If present, we also intended to determine the 
mechanism of action and functional effects of any observed injury that might lead 
to therapeutic intervention, analogous to our previous approach to the 
neuromuscular junction. 
 Materials and methods 
 
Mice 
Male GD3 synthase knockout mice (GD3s-/-) mice (Okada et al., 2002) were 
crossed with B6/Cg-TgN(Thy1-CFP) x DBA mice that endogenously express 
cyan fluorescent protein (CFP) in their axons (Feng et al., 2000, kindly provided 
by Dr W. Thompson, Austin, Texas) to produce a doubly genetically modified 
mouse referred to as GD3s-/-/CFP in this study. GD3s-/- mice were preferentially 
used as they express greater amounts of axonal GD1a compared with their wild 
type (WT) counterparts, owing to blockade of b-series biosynthesis and 
consequent accumulation of a-series gangliosides including GD1a. The 
ganglioside biosynthetic pathway illustrating this is shown in Fig. S1. Through 
virtue of expressing high amounts of GD1a, GD3s-/- mice bind more anti-GD1a 
antibody than their wildtype (WT) counterparts as previously reported at motor 
nerve terminals (Goodfellow et al., 2005). In order to confirm that GD3s-/-/CFP 
were an appropriate cross in which to model these experiments, binding of anti-
GD1a antibody was quantified in GD3s-/-/CFP mice in comparison with WT/CFP 
controls (Fig. S2). Mice were killed by CO2 inhalation at 6-12 weeks of age and 
experiments were carried out under licence (PPL60/3842) in accordance with UK 
Home Office guidelines. 
 
Antibodies and reagents 
The IgG2b mAb to GD1a (herein termed anti-GD1a antibody, also known as 
MOG-35) was produced by immunisation of GalNAcT-/- mice (lacking all complex 
gangliosides (Takamiya et al., 1996), with the Campylobacter jejuni HS:19 LOS 
strain that possesses structures identical to GD1a to which it raises a cross-
reactive immune response (Bowes et al., 2002)] and acts as an antecedent 
infection in AMAN, as described (Boffey et al., 2005). Antibodies to channels, 
other proteins and membrane attack complex (MAC), C5b-9 are detailed in Table 
1. Eculizumab, a humanised anti-human C5 mAb that binds plasma C5 to 
prevent MAC formation and ALXN3300 (the isotype-matched control mAb) were 
supplied by Alexion Pharmaceuticals (Cheshire, USA). The synthetic peptide 
AK295 binds calpain I, II and cathepsin B to prevent their activation and 
proteolytic action (Li et al., 1996). Toxins were used as follows: α-bungarotoxin 
(BTx, Molecular Probes, UK) Alexa Fluor 488 and 647 conjugates at 1:500; α-
latrotoxin (LTx, Alomone Labs, Israel) at 12nM; tetrodotoxin (TTX, Biotium Inc, 
USA) at 5μM; vecuronium (Organon Laboratories Ltd, Cambridge, UK) at 5µM. 
 
Ex vivo and in vivo muscle and nerve permeability studies  
Triangularis sterni (TS) muscle, phrenic nerve, sural nerve and sciatic nerve were 
dissected, mounted and maintained alive in Ringer’s medium (116mM NaCl, 
4.5mM KCl, 1mM MgCl2, 2mM CaCl2, 1mM NaH2PO4, 23mM NaHCO3, 11mM 
glucose, pH 7.4) pre-gassed with 95% O2/5% CO2 at room temperature (~20°C). 
Muscle and nerve (desheathed by slitting and opening the epineurium with a fine 
needle, or left intact) were incubated with 100μg/ml anti-GD1a antibody for 2h at 
32°C, 30mins at 4°C and a final 10mins at RT, plus BTx to label NMJ. Antibody 
control preparations were incubated with Ringer’s alone. Preparations were 
rinsed in Ringer’s prior to fixation in 4% paraformaldehyde (20mins, RT). Tissue 
was then rinsed in PBS, 0.1M glycine and PBS (10mins each, R.T.). Tissue was 
incubated with anti-IgG2b-FITC (1:200) and the pan anti-neurofascin antibody 
NFC2 (1:1000) with 0.5% Triton X-100 in blocking solution (1% goat serum and 
1% L-lysine) overnight at 4°C. Intramuscular nerve bundles were divided into four 
categories for quantification: single fibres, small bundles (<15μm), medium 
bundles (15-35μm) and large bundles (>35μm). NoR were identified by 
neurofascin staining and the anti-GD1a antibody immunofluorescence at this 
region were measured within each category and compared to control tissue.  
To study the binding of antibody in vivo, the same quantification was performed 
on TS muscle removed from a mouse injected i.p. 16h previously with 3mg anti-
GD1a antibody. PBS was used for control groups. 
For sciatic, sural and phrenic nerves, in order to assess antibody and 
complement access through the relatively impermeable epineurium, and 
therefore vulnerability to injury, isolated nerves were incubated ex vivo with anti-
GD1a antibody under intact and desheathed conditions. It was thereby 
established that desheathing was essential for achieving anti-GD1a antibody 
binding at NoR in nerve trunks, and that under these conditions antibody binding 
levels were equivalent to intramuscular nerve NoR. Data for the phrenic nerve is 
shown in Fig. S3. All studies on nerve trunks were thus conducted on 
desheathed nerves.  
 Ex vivo preparations for complement activation and nodal protein disruption 
Muscle and nerve preparations were subjected to the same protocols as used for 
assessing permeability, with the additional step that tissue was incubated with 
40% normal human serum (NHS) for 3h at RT prior to fixation. Muscle was 
cryosectioned at 10μm and stained for MAC, nodal channels and other proteins 
overnight at 4oC as listed in Table 1. In order to identify NoR, fluoromyelin green 
(1:400) that labels lipids, or dystrophin (1:200) that labels the myelin sheath were 
applied. Secondary antibodies were applied for 3 hrs at RT as follows: anti-rabbit 
IgG-Cy5 (1:300) for Nav1.6, Caspr, NFC2, Kv1.1, neurofilament; anti-mouse 
IgG1-Cy5 (1:300) for ankyrin G, moesin, NrCAM and dystrophin; anti-mouse 
IgG2a-TRITC (1:200) for MAC. NoR with a normal immunostaining pattern for 
nodal proteins were scored as present or absent/abnormal. To determine 
whether any abnormal immunostaining was dependent on nodal MAC deposition, 
or resultant from an upstream effect of massive synaptic injury, Nav1.6 
immunostaining at NoR was compared between antibody treated and α-LTx 
treated tissue. Our previous studies have shown that the nerve terminal effects of 
antiganglioside antibodies mimic those of α-LTx (Plomp et al., 1999;Plomp and 
Willison 2009) . α-LTx was added at 2nM in Ringer’s to the organ bath at the 
same time NHS was added in a parallel preparation. 
To assess the contribution of MAC to any observed injury, the C5 inhibitor 
Eculizumab was added at 100μg/ml to NHS 10mins prior to incubation with the 
muscle. To investigate the contribution of calpain, 100μM of the calpain inhibitor 
AK295 (kindly provided by Dr J. Powers and J. Glass, Atlanta, Georgia), was 
added concurrently with NHS. Eculizumab concentration had been previously 
optimised (Halstead et al., 2008b). AK295 was optimised for concentration by 
dose ranging studies from 25-200 micromolar concentrations and the lowest 
concentration that fully protected protein cleavage was used. In Eculizumab-
treated and -unprotected intramuscular axons, the presence of axonal CFP was 
used to monitor axonal integrity. After AK295 treatment, the intensity of 
neurofilament immunoreactivity was quantified at the nerve terminal as 
delineated by BTx staining and compared to AK295-unprotected tissue levels. 
The efficacies of Eculizumab and AK295, as monitored by immunostaining 
profiles, were expressed as the percentage of protected versus unprotected 
signals at the relevant NoR sites. 
 
Perineural and extracellular recordings 
TS nerve-muscle preparations were freshly dissected and set up ex vivo for 
electrophysiological recordings as for immunocytochemisrty studies. Experiments 
were carried out at room temperature (20-22°C) using 2 M NaCl-filled 
microlectrodes with a resistance of 25-45 MΩ in preparations bathed in Ringer’s. 
Recordings were made from nerve terminals and small and large intramuscular 
nerve bundles after anti-GD1a antibody incubation followed by NHS for 3hrs. 
Perineural waveforms associated with nerve terminal action potentials were 
made as previously described (Braga et al., 1991). Muscles were paralysed with 
5 µM vecuronium to prevent twitching. In some experiments the same 
microelectrode was used to measure muscle resting membrane potentials. 
Signals were amplified, recorded and analysed as per the nerve extracellular 
recordings below. 
For extracellular recordings, nerves were mounted in a custom made 
Perspex recording block across three chambers and sealed in with vacuum 
grease. Nerves were stimulated with a Grass S88 stimulator delivering pulses at 
a frequency of 1Hz, and at a supramaximal voltage. Signals were amplified via a 
CED1902 and digitised by a NIDAQ-MX A/D converter (National Instruments, 
Austin, Texas), then captured and analysed using WinWCP version 4.1.0 
software. Phrenic nerves and sural nerves remained in the recording chamber 
throughout the experiments and recordings were made for 2h on the application 
of NHS. Recordings from the larger sciatic nerve were collected on transfer of the 
nerve to the recording chamber following NHS treatment in a petri dish, as 
penetration of NHS into the nerve was not uniformly maximal whilst in the 
recording chamber. At the termination of all experiments 5µM TTX was added to 
the recording chamber to confirm that the waveform being recorded was the 
result of the opening of sodium channels. A representative graph of the positive 
peak value of compound action potential (CAP) over time was plotted to convey 
conduction. A minimum of 200 control waveforms were averaged prior to the 
addition of NHS. Absolute CAP values were not presented as these varied 
between experiments; instead the percentage of the starting CAP peak value 
was calculated for each of 3-5 preparations and averaged for each treatment 
group. A 2-sample t-test was used for comparison of phrenic and sural nerve 
conduction, whilst a paired t-test was performed for comparison of sciatic nerve 
CAP recordings.  
 
Image acquisition and analysis 
Fluorescent images were captured on both a Zeiss Axio Imager Z1 with 
ApoTome attachment and a Zeiss Pascal confocal laser scanning microscope. 
Image analysis was carried out using ImageJ software. For quantitative analysis 
of antibody and MAC deposition, the fluorescence signal at the region of the NoR 
was measured and any background fluorescence subtracted. Where relevant, 
measurements were categorised by bundle size as described above. The same 
procedure was carried out for the quantitation of neurofilament signal over the 
motor endplate. Measurements were pooled from three experimental 
preparations and presented as box and whisker plots to represent the spread of 
the non-parametric data. Mann-Whitney mean rank test was used to compare 
possible statistical differences between groups where the level of significance 
was set at 1%. For comparison of nodal protein immunostaining, NoR positive for 
individual markers were counted for each bundle category and the chi-squared 
test used at a 1% level of significance. 
Results 
 
Anti-GD1a antibodies are preferentially deposited at distal motor nerve nodes of 
Ranvier. 
Anti-GD1a antibody was applied to TS muscle preparations from GD3s-/-/CFP 
mice maintained ex vivo in organ baths and its deposition immunolocalised and 
quantified at the NoR in double staining studies. Anti-GD1a antibody binds 
intensely at the motor nerve terminal of GD3s-/- mice (Fig. 1A; upper area of 
image) as shown in previous studies (Goodfellow et al., 2005). In relation to the 
present study, anti-GD1a antibody deposits are prominent at the NoR of distal 
intramuscular axons, as illustrated here by co-localisation with the nodal and 
paranodal marker, pan-neurofascin antibody (Fig. 1A). The juxta-terminal NoR 
bear the most prominent antibody deposits; thus the fluorescence intensity of 
anti-GD1a antibody deposits observed at NoR decreases with increasing 
distance from the nerve terminal. In order to quantitatively assess this, 
intramuscular nerve bundles were categorised into 3 groups (Fig. 1B). The single 
arrow indicates a single fibre; double arrow a small bundle (<15µm); and triple 
arrow a medium bundle (15-35µm). A further category of large nerve bundles 
was assigned for bundle diameters exceeding 35µm; this category is not shown 
in Fig. 1B as none were evident in this distal area of the intramuscular nerve 
complex. Anti-GD1a antibody applied to TS muscle preparations ex vivo were 
deposited at significantly higher levels at single fibre NoR compared to all other 
bundle categories and control tissue (Fig. 1C, D; P<0.001). This was also evident 
for small bundles (P<0.001) and medium bundles (P=0.0023). Large bundles had 
an insignificant anti-GD1a antibody deposition level, comparable to control 
tissue, suggesting anti-GD1a antibody was unable to gain access to bundles of 
this size following topical application. In order to assess anti-GD1a antibody 
penetration to these intramuscular nerve compartments when delivered through 
the vascular bed (as opposed to organ bath incubation), anti-GD1a antibody was 
injected intraperitoneally, and 16 hours later the TS muscle was removed for 
antibody quantification, as for ex vivo preparations above. Equivalent results to 
the ex vivo findings were observed, with antibody deposits being greatest in the 
distal part of the nerve in a gradient-dependent manner when categorised by 
bundle size (Fig. 1E). In order to establish that these differences were not due to 
a proximal to distal gradient of GD1a expression at NoR in nerve, frozen sections 
of permeabilised intramuscular nerve bundles in which antibody access is 
expected to be uniform were stained with anti-GD1a antibody, and the signal 
intensity was found to be the same, irrespective of the nerve bundle size (Fig. 
S4). These ex vivo and in vivo findings demonstrate that anti-GD1a antibody is 
able to bind to intramuscular nerve NoR in a distal to proximal downward 
gradient, presumed due to the relatively increasing impermeability of the BNB to 
antibody as bundle size increases. 
 
Nodal proteins are disrupted and distal motor nerves are rendered inexcitable by 
anti-GD1a antibody directed complement activation 
In our previously reported model of anti-ganglioside mediated injury to the 
nerve terminal, complement activation has been monitored by heterologous 
(human) MAC deposition at motor nerve terminals (Plomp and Willison2009). 
Similarly in this study, MAC deposition was demonstrated at NoR of the distal 
intramuscular nerves in response to the addition of an exogenous source of 
human complement in the form of NHS (Fig. 2A). As with anti-GD1a antibody 
deposition, MAC deposition as assessed by fluorescence intensity for anti-MAC 
antibody was gradient-dependent, with significantly higher levels of fluorescence 
observed at single fibre NoR compared to all other categories (Fig. 2B; P<0.001) 
and significantly higher MAC levels at small bundle NoR compared to larger 
categories (Fig. 2B; P<0.001). Axonal injury was further characterised by the 
complete loss of the endogenous axonal CFP signal, both at the nerve terminal 
and along the distal axon as illustrated in Fig. 2C. Even in large bundles, the CFP 
signal was relatively attenuated in antibody plus NHS treated preparations. 
In order to assess the functional effect of MAC deposition to the distal 
axonal region, electrophysiological assessment of local ion currents was 
performed by recording perineural currents. End plate microelectrode recordings 
would not be useful to assess this as all our previous electrophysiological studies 
have shown that the motor nerve terminal is irreversibly paralysed in this model 
(Plomp and Willison, 2009). Perineural recordings were made at the nerve 
terminal, at small nerve bundles and at large nerve bundles. In control tissue 
(anti-GD1a antibody without NHS), biphasic waveforms (see discussion for a 
fuller account of the nature of the waveform) were observed that correspond to 
currents flowing through Na+ and K+ channels respectively (Fig. 2D, top panels). 
After treatment of tissue with anti-GD1a antibody plus NHS as a complement 
source, there was a complete loss of both K+ (broken arrow) and Na+ (solid 
arrow) current flow at the nerve terminal and nerve bundles, with the exception of 
preserved Na+ current in large bundles (Fig. 2D, lower panel, arrow).  
To investigate the structural correlate of this complement-associated loss 
of function, the architecture of the NoR was investigated by analysing the nodal 
appearance under phase microscopy and by immunostaining for NoR proteins 
located at various nodal sub-domains under injurious conditions. Electron 
microscopy of the NoR was also conducted; however the control tissue, having 
been exposed to organ bath conditions for ~5hours prior to fixation showed 
significant artefactual abnormalities, rendering this method assessment of any 
additional pathology at the experimentally injured NoR inappropriate. The 
percentage of NoR with intact staining for NaV1.6, the sodium channel isoform 
expressed at the peripheral nerve NoR (Caldwell et al., 2000) was reduced 
(<90%) in single fibres and small bundles after treatment, compared to control 
(Fig. 3A; P<0.001). The cytoskeletal protein ankyrin G was similarly affected (Fig. 
3B; P<0.001), as was the paranodal axolemmal protein Caspr (Fig. 3C; 
P<0.001). Staining for neurofascin was partially lost at single fibre and small 
bundle NoR (Fig. 3D; P<0.001 and P=0.001, respectively), and at NoR where it 
was preserved, the pattern was disrupted. Immunostaining to the potassium 
channel Kv1.1 localised to the juxtaparanode was unaffected in all bundle 
categories (Fig. 3E). 
 The complete and rapid disappearance of key NoR component proteins as 
assessed by immunostaining following 3hrs of NHS exposure was striking. In 
order to assess this in more detail for Nav1.6, intermediate stages of dissolution 
of Nav1.6 immunostaining were qualitatively examined at 15mins and 30mins 
after the addition of complement treatment. At 15min there was no alteration to 
staining; however by 30mins a proportion of NoR developed punctuate and 
dispersed Nav1.6 staining, indicating fragmentation and spread of Nav1.6 
channel clusters bound by the anti-Nav1.6 antibody, examples for 3 separate 
NoR being shown in Fig. S5. 
In this model, the motor nerve terminal is also severely and concomitantly 
injured such that it might conceivably have more proximal motor axonal 
consequences. By way of control to ensure that the observed nodal protein 
staining loss was associated with MAC deposition and injury directly at the NoR, 
Nav1.6 staining at NoR was assessed after α-LTx-induced injury that creates a 
nerve terminal lesion identical to that of anti-GD1a antibody directed MAC (Fig. 
S6). Nav1.6 immunostaining was still intact after LTx treatment, thereby 
confirming that its loss is due to anti-GD1a antibody with local complement 
activation at NoR. Taken together these results suggest that anti-GD1a antibody 
directed complement-mediated disruption to the nodal architecture of the distal 
axons results in a block in nerve conduction.  
 
Complement inhibition completely protects nodes of Ranvier from anti-GD1a 
antibody-mediated injury 
In order to demonstrate the role for the MAC component of complement 
activation, the C5 complement inhibitor Eculizumab, that completely prevents 
MAC assembly, was introduced to the organ bath model. Eculizumab protected 
Nav1.6, ankyrin G and Caspr immunostaining at NoR from injury mediated by 
complement activation, compared with the isotype control antibody ALXN3300. In 
quantitative analysis, the percentage of NoR with intact Nav1.6 staining is 
significantly greater on the addition of Eculizumab compared to the isotype-
matched control mAb ALXN3300 at single fibres and small bundles (Fig. 4A; 
P<0.001). As demonstrated previously, there was no reduction in immunostaining 
at medium and large bundles in response to complement and thus complement 
inhibition could not further attenuate this. Single fibre and small bundle NoR also 
had significantly preserved ankyrin G and Caspr staining with Eculizumab 
protection compared to ALXN3300 application (Fig. 4B,C; P<0.001). Additionally, 
endogenous CFP was maintained in axons and bundles with Eculizumab 
treatment compared to ALXN3300, essentially maintaining the normal overall 
architecture with a normal appearance (Fig. 4D). 
 
Calpain inhibition protects Na channel and axonal protein integrity without 
preserving nerve currents 
A major consequence of MAC pore deposition in plasma membranes is the 
formation of a bi-directional, non-specific ion and water pore. At the NoR, the 
electrical function of the nodal axolemmal membrane is dependent upon tightly 
regulated ion homeostasis and the consequences of this uncontrolled flux are 
likely to be considerably detrimental. One harmful ion flux mediated by MAC 
pores is the calcium ingress that activates calpain. To assess the consequence 
of the calcium component of ion influx, the protective effect of the synthetic 
calpain inhibitor AK295 was investigated. Neurofilament is a known calpain 
substrate (Chan and Mattson 1999) and its protection by calpain inhibition in 
response to anti-ganglioside antibody-mediated complement-dependent injury 
has been reported previously in our nerve terminal mouse model of GBS 
(O'Hanlon et al.,2003). In the present study, neurofilament at the NMJ was also 
significantly protected by 100μm AK295 treatment compared to antibody and 
NHS treated, AK295 unprotected tissue (Fig. 5).  
At the NoR in ex vivo whole-mount TS muscle preparations exposed to 
antibody and NHS with and without AK295, assessments of Nav1.6, ankyrin G 
and Caspr immunostaining, and of perineural electrophysiological recordings 
were made. As expected, the extent of MAC deposition at NoR was completely 
unaffected by AK295 (data not shown). Nav1.6 immunostaining at single fibre 
and small bundle NoR was almost completely protected by AK295 treatment 
compared to unprotected treated muscle (Fig. 6A; P<0.001). Ankyrin G and 
Caspr immunostaining was equally protected by calpain inhibition at single fibre 
and small bundle NoR (Fig. 6B,C; P<0.001). For all nodal markers, the staining at 
NoR in medium and large bundles did not significantly differ as injury does not 
occur at these more proximal NoR.  
To functionally assess the protective properties of AK295, perineural 
recordings were conducted as previously Fig. 6D. Compared to normal control 
tissue currents, perineural Na+ and K+ currents were adversely affected by anti-
GD1a antibody plus NHS, despite the presence of AK295. Thus, a similar loss of 
current flow to that seen in injured tissue as shown in Fig. 2D (lower panel) was 
observed. These data indicate that calpain inhibition is able to prevent the 
destruction of major structural components at NoR, included Nav1.6 channels, 
but that despite this, loss of nodal conduction as assessed electrophysiologically 
still occurs.  
 
Nodes of Ranvier in the nerve trunks are also vulnerable to anti-GD1a antibody 
and MAC-mediated calpain activation 
Whilst distal intramuscular nerve NoRs were the predominant target site 
investigated in this study, more proximal nerve trunks were also studied for 
vulnerability to anti-GD1a antibody mediated attack. The aims of examining 
nerve trunks were several-fold: a) to exclude the possibility that the vulnerability 
to anti-GD1a antibody-mediated injury was due to a distal to proximal GD1a 
antigen gradient in nerves (rather than a reflection of antibody access); b) to 
exclude the possibility that concomitant, latrotoxin-like nerve terminal injury was 
responsible for any disruption to the juxta-terminal NoRs examined in nerve-
muscle preparations; c) to assess any distinction between motor and sensory 
nerve vulnerability; and d) to provide additional electrophysiological evidence in 
support of the perineural recording data through CAP recordings in nerve 
bundles. Experiments on nerve trunks were conducted with anti-GD1a antibody 
and NHS as the complement source, in the presence and absence of calpain 
inhibition with AK295.  
Preliminary studies were conducted on desheathed sciatic nerve that 
contains both motor and sensory fibres, chosen for its ease of dissection and 
widely recognised applicability to CAP measurement in recording chambers. 
Control nerves were compared with antibody and complement treated nerves 
(see materials and methods).  In sciatic nerve, anti-GD1a and complement 
deposits were observed widely and significantly at NoR, but with some variation 
in complement fixation product within bundles and from fascicle to fascicle (data 
not shown). CAP recordings, expressed as a percentage of starting values, 
showed only a modest reduction in amplitude in treated nerves (87.3 ± 16%) 
compared with control nerves (109 ± 5.3%) which was not significant (paired t-
test, p=0.2). Illustrative traces are shown in Fig S7 panel A. 
Subsequently a predominantly motor nerve (phrenic; 70% of myelinated 
fibres being motor, Langford and Schmidt 1983) and purely sensory nerve (sural) 
were investigated in parallel, one advantage being that these nerves could 
remain in the recording chamber throughout the experimental incubations with 
NHS as the complement source, and continuous serial recordings could thus be 
collected, followed by end-point immunohistology. Anti-GD1a antibody and 
complement (MAC) deposition was present at NoR in both phrenic and sural 
nerve; however their appearance was significantly different, being more 
elongated in distribution across the NoR in phrenic nerve compared to sural 
nerve (Fig. 7A), an observation that could be readily quantitated (Fig. 7B; 
P<0.001) . Furthermore, sural nerve NoRs with antibody and MAC deposits and 
yet intact Nav1.6 channel immunostaining was often observed (Fig. 7C), a finding 
not seen in the phrenic nerve or its intramuscular branches. In terms of functional 
effects on CAP amplitudes, sural nerve CAPs remained stable or only modestly 
reduced over time (76.3 ± 9.6%; Fig S7 panel B), which was not significantly 
different from controls. 
In phrenic nerves, immunostaining of Nav1.6, ankyrin G and Caspr at NoR 
was quantified in response to anti-GD1a and NHS exposure. Having 
demonstrated nodal protein loss upon NHS exposure, experiments were also 
conducted in the presence and absence of AK295 (calpain inhibition) as for the 
ex vivo TS preparation. Immunostaining of the extracellular domain of NrCAM, 
and moesin (a Schwann cell microvillal component) was also assessed, these 
being molecules within the nodal complex but predicted to be unaffected by 
calpain cleavage directly (Fig. S8). There was a significant loss of 
immunostaining to Nav1.6, ankyrin G and Caspr in nerve exposed to antibody 
and complement, compared to control (Fig. 8A, C; P<0.001). Unlike the reduction 
in Nav1.6, ankyrin G and Caspr staining, the NrCAM and moesin staining was 
retained but appeared mislocalised, being more diffusely spread throughout the 
NoR area in comparison with the staining pattern in control tissue (Fig. 8A, C).  
Nav1.6 channel and Caspr staining was significantly protected by AK295 
(Fig 8B; P=0.01 for both proteins), although this was more modest when 
compared with the levels of protection achieved at the distal nerve NoR. 
Protection of ankyrin G staining followed the same trend but did not achieve 
significance (P=0.14). The retained but disrupted pattern of NrCAM and moesin 
immunostaining was not altered by AK295 treatment.  
Under phase optics (differential interference contrast, DIC), a constant 
feature observed in phrenic nerve subjected to MAC deposition and injury was 
the swollen, granular appearance of the NoR, in comparison with control tissue, 
as visible in images (Fig. 8C). This subjective and unquantifiable appearance 
was unaffected by AK295 treatment (Fig 8C, top row ) but was consitently 
present. 2 examples of each antibody staining pattern are shown for AK295 
protected NoR (Fig 8C, R hand panels). Extracellular recordings of phrenic nerve 
CAPs showed a large fall in amplitude over time (to 40.5 ± 10.7%) after treatment 
with anti-GD1a antibody and complement, in comparison with peak amplitude of 
the CAP prior to complement exposure. (Fig 8D, E). This fall in CAP amplitude 
was not significantly prevented by AK295 treatment (15.0 ± 8.7%, P=0.3). 
 Discussion 
 
This study presents 3 major findings that develop our knowledge of nerve injury 
in anti-GD1a ganglioside antibody-mediated acute neuropathy models. Firstly, 
we demonstrate the increased vulnerability of very distal intramuscular NoR to 
antibody and complement mediated injury, in comparison with more proximal 
nodes that are relatively protected by the blood nerve barrier. Secondly, we show 
that axolemmal MAC pores at NoR result in calpain activation that in turn causes 
a) immunodetectable loss of key protein components of the nodal complex 
including Nav1.6 channels, most likely by protein cleavage leading to 
fragmentation (Iwata et al., 2003, von Reyn et al., 2009), and b) loss of function 
as demonstrated by the inability to record nerve terminal action potentials in 
distal axons. Implicit in the inhibition studies that demonstrated the involvement 
of complement and calpain activation, we infer that blockade of these 
pathological processes could be exploited therapeutically. Thirdly, we show that 
electrical inexcitability of the NoR induced by MAC pores can occur in the 
presence of preserved gross structural integrity including that of key protein 
components (Nav1.6, ankyrin, Caspr), suggesting that failure of the axolemmal 
membrane to maintain ionic homeostasis when punctured by MAC pores is the 
critical factor in mediating axonal conduction block in this model.  
 The study has been facilitated by new investigative approaches. Firstly, 
we established that intramuscular motor nerve NoR provide a simple site 
relatively devoid of blood nerve barrier restrictions for analysing the pathological 
effects of locally or systemically delivered autoantibodies that might target this 
site, both ex vivo and in vivo (Burkel1967; Malmgren and Olsson1980; 
Olsson1990). As part of this we mapped the antibody access gradient in 
intramuscular nerve bundles, allowing us to identify and focus attention on the 
most vulnerable distal sites. We also demonstrated that any distal NoR effects 
did not result from concomitant latrotoxin-like, pre-synaptic injury that occurs in 
this model (Duchen et al., 1981;Plomp and Willison, 2009). A particular 
advantage of this preparation is that it allows for concomitant experimentation on 
neuromuscular junctions and NoR, although the former site was not assessed in 
this study as it has been previously addressed (Goodfellow et al., 2005). 
Secondly we have exploited genetically modified mice in which ganglioside 
antigen (and consequentially antibody binding) levels can be controlled, crossed 
with constitutive fluorescence for easy identification of intramuscular axons (Feng 
et al., 2000; Okada et al., 2002). The development of mouse models that display 
structural and functional similarities to the disease process in humans is an 
important goal for understanding mechanism and therapies. Models have 
limitations, in that only restricted elements of the human pathological cascade 
are monitored under very controlled conditions; however this also provides 
opportunities for unique insights into pathogenesis as highly selected events can 
be tracked in their entirety. Thus in this study we have precisely established the 
nature of acute pathological and electrophysiological events that result from MAC 
injury to NoR and their therapeutic responsiveness, events that would never be 
tractable either in man or in longer term in vivo animal studies. 
 The application of perineural recordings to electrophysiologically monitor 
NoR in our studies was also critical as we know from extensive prior work that 
the motor end plate is concomitantly paralysed in this model, and as a result 
measurement of endplate potentials or muscle action potentials was not a viable 
means to indirectly assess NoR function. The size and location of nerve 
terminals at mammalian motor neuromuscular junctions has made it a huge 
technical challenge to employ conventional intracellular or patch clamp recording 
techniques to directly record the electrical activity of neurons. However, the 
perineural recording technique allows for the recording of local electrical signals, 
resulting from the opening of ion channel from the preterminal, terminal and 
axonal regions of motor neurons (Brigant and Mallart, 1982 Mallart, 1985). When 
an electrode is inserted through the perineural sheath of a motor nerve close to 
nerve terminals a waveform composed of two negative spikes can be recorded 
upon nerve stimulation. The first negative spike is attributed with inward Na+ 
current (sensitive to TTX) at the nodes of Ranvier in the axonal trunk, and the 
second negative spike represents the net local circuit current generated by the 
large outward current of K+ and a relatively small inward Ca2+ current at motor 
nerve terminals. By convention the first negative deflection is referred to as a Na+ 
current (INa) and the second negative deflection is a K+ current (IK).  
The loss of recordable perineural currents in a distal-dominant pattern 
correlated well with our immunohistological findings. At the distal NoR, the 
absence of recordable currents indicates a severe disruption of the ability of the 
NoR and motor nerve terminal to generate Na+ and K+ currents respectively. This 
may either be due to calpain cleavage of the channels directly, or due to the 
inability of the injured axon to maintain a resting membrane potential in the 
presence of MAC pores. The perineural current data obtained in the presence of 
calpain, in which channel integrity is preserved, indicate the latter mechanism is 
more likely, as discussed further below. In the large intramuscular nerve bundles 
which are relatively resistant to injury, we found the Na+ current to be relatively 
preserved whereas the K+ current was reduced or absent, and interpreted this as 
an inability to generate or propagate an action potential in the severely affected 
distal motor nerve that would be required to activate the terminal’s voltage 
dependent K+ channels. Even though antibody and complement levels were 
undetectable in large intramuscular bundles, the attenuation of the CFP signal in 
these bundles (as seen in Figure 2C) suggests that some level of injury with 
resultant CFP leakage is taking place, but at an insufficient level to ablate either 
the Nav1.6 immunohistology signal, or the perineural Na+ current. Whilst these 
explanations derive from current recording data that is indirectly linked to specific 
channel function, they nevertheless offer an internally consistent interpretation of 
our observations and are also consistent with our previous experiments in which 
mono-phasic waveforms (Na+ current) result from loss of sodium channel 
function with apparent block of the K+ current (Braga et al., 1992). 
 Our previous studies have shown that the nerve terminal in this mouse 
model of anti-GD1a antibody-mediated AMAN is dependent upon MAC 
deposition (Goodfellow et al., 2005; Willison et al., 2008), and can be completely 
attenuated by the C5 neutralising antibody, Eculizumab (Halstead et al., 2008b) . 
Here we also demonstrate the pivotal role for complement in mediating the 
disorganisation of the NoR, and its inhibition by Eculizumab, thereby supporting 
our previous work. This also supports data from an active immunisation model of 
AMAN in rabbits in which ventral root NoR are targeted by anti-GM1 antibody 
and complement that can be inhibited by Nefomstat mesilate, although the 
precise mechanism(s) underlying this protection may be different (Phongsisay et 
al., 2008). This raises the therapeutic prospect of using Eculizumab in AMAN and 
GBS patients, as has been achieved in other MAC mediated disorders (Hillmen 
et al., 2006).  
 The MAC pore, like many other pore forming toxins, comprises a 
transmembrane doughnut-shaped channel of ~5nm pore size that allows 
unselective, bidirectional flow of water, ions and soluble intracellular constituents 
(Podack et al., 1982; Lacovache et al., 2008) including CFP. Thus in this model, 
the outward flow of CFP and its subsequent dilution in the extracellular 
environment (accounting for its disappearance; it is not a calpain substrate) 
appears to be a very sensitive marker of pore formation. Even in the large 
intramuscular nerve bundles in which MAC is undetectable, the CFP signal is 
attenuated, although this may alternatively be due to diffusion down axon with 
subsequent leakage in the more distally injured region. 
At the NoR under physiological conditions in which it is bathed in 
extracellular fluid, or exposed to Ringer’s (containing 2mM Ca2+ as present in our 
ex vivo preparations), extracellular Ca2+ will flow intracellularly through MAC 
pores where one effect will be to activate the ubiquitous family of calcium 
activated cysteine proteases, or calpains, as we have previously shown for the 
nerve terminal (O'Hanlon et al., 2003). Calpain-mediated proteolysis cleaves a 
wide range cytoskeletal and membrane proteins (Vosler et al., 2008), and the 
protective consequence of its pharmacological inhibition provides the evidence of 
its activation, as demonstrated here. Ankyrin G and neurofilament proteins are 
long known calpain substrates and more recent in vitro studies have also 
identified the sodium channel as a calpain substrate (Iwata et al., 2004; von Reyn 
et al., 2009). Our finding of Nav1.6 protection by calpain inhibition, as 
demonstrated by preserved immunostaining, supports these reports. Both of the 
Nav.1.6 antibodies we used (see Table 1) bind to peptide domains on calpain-
susceptible intracellular cytoplasmic loops between transmembrane channel 
subunits. Thus, the apparent ‘disappearance’ of Nav1.6 observed in this study 
over such a short timeframe most likely equate to cleavage of the cytoplasmic 
loop(s), rather than a more global disintegration, internalisation, or shedding of 
Nav1.6. Moreover, proteolysis of Nav1.6 intracellular loops may not majorly affect 
channel function, since activation is preserved, the dominant effect being a 
failure of inactivation (von Reyn et al 2009). Since ankyrin G links Nav1.6 to the 
cytoskeleton, it is equally possible that the un-tethered Nav1.6 becomes 
mislocalised through lateral diffusion; indeed multiple effects of MAC-mediated 
injury are likely. Our attempts to identify channel fragments by Western blotting 
were unsuccessful, owing to the minute amounts of Nav1.6 protein fragments in 
either phrenic nerve or neuromuscular preparations (data not shown). The 
mislocalised but preserved immunostaining of Kv1.1 at the juxtaparanode, 
moesin in the Schwann cell microvilli, and the extracellular domain of NrCAM at 
the NoR, alongside the phase optics images of the NoR, strongly suggests that 
highly selective injury to the NoR axolemma was accompanied by local swelling 
and disorganisation, with grossly preserved structural integrity of the glial-axonal 
unit over this timeframe. The mechanistic similarities between this model and the 
Nav1.6 loss at ventral root NoR recently reported in the more chronic rabbit 
model of anti-GM1 antibody-mediated AMAN are intriguing, but unknown (Susuki 
et al., 2007b) . 
Functional performance of the NoR under these injurious conditions was 
assessed with particular attention to Nav1.6, owing to its central role in nodal 
conduction. Injured NoR rapidly became electrically inactive, even when Nav1.6 
and other calpain substrates were protected by AK295 treatment; indicating that 
failure to maintain ionic and water homeostasis owing to the presence of MAC 
pores, leading to membrane depolarization and inactivation of Nav1.6 channels, 
was the most likely mechanism, rather than Nav1.6 disruption. Similar 
conclusions were drawn following our studies at the nerve terminal in which the 
calpain inhibitor calpeptin was ineffective at protecting function or ultrastructure, 
although the neurofilament integrity was preserved (O'Hanlon et al., 2003). 
Ideally, ultrastructural examination of NoR would inform this; however electron 
micrographs of both control and affected NoR all showed fixation-related 
artefacts owing to the extended periods of time the nerve was maintained ex 
vivo, and were not suitable for analysis. In the previously reported rabbit model of 
AMAN, ultrastructural examination of the NoR demonstrated the extension of the 
nodal gap and the detachment of paranodal loops although these images were 
collected after a more prolonged period of injury, as noted above (Susuki et al., 
2007b). 
Our experimental transition in this study from intramuscular nerve bundles 
to nerve trunks provided comparable and supportive immunohistological and 
electrophysiological evidence. It also unearthed a differential sensitivity of motor 
(phrenic) and sensory (sural) nerves to MAC mediated injury that remains 
unexplained. Whether this quantitative or qualitative resistance of sural nerve to 
MAC-mediated injury provides insights into human AMAN, in which motor nerves 
are selectively affected, is unknown. In the currently used GD3s-/- mouse model, 
the sural nerve contains GD1a that is sufficiently available for antibody binding 
with complement activation, whereas in man the levels of GD1a available for 
antibody targeting is most likely greater in human motor than sensory nerve (De 
Angelis et al., 2001; Gong et al., 2002). 
The above model describing very distal injury as a feature of AMAN 
corresponds well with existing clinical data, notwithstanding the co-occurrence in 
some cases of severe proximal injury (Ho et al., 1997; McKhann et al., 1991). In 
terms of underlying molecular mechanisms, the acute and severe motor NoR 
injury in this model may correspond to the initial phases of axonal conduction 
block seen in human AMAN, in which rapid onset but potentially reversible 
pathophysiology develops, prior to any cellular infiltration or axonal degeneration. 
The extent to which such events occur in man cannot be readily determined at a 
pathophysiological level as clinical and electrophysiological interrogation is very 
limited; however recovery in AMAN may be either very rapid and complete, or 
very prolonged with poor outcome, owing to extensive proximal axonal 
degeneration (McKhann et al., 1993; Hiraga et al., 2005b). The events at the 
NoR described here would correspond well with the early injury phase of a 
dichotomous outcome model (Gabriel 2005). Critically, inhibition of the terminal 
complement product, MAC, as an early intervention seems essential from these 
data to limiting both acute injury, and the development of more destructive long 
term pathology, whilst the inhibition of calpain activation downstream from MAC 
may also offer some partially additive benefit. The expectation that clinical trials 
of complement or calpain inhibition in GBS and its variants will inform this further 
is considerable (Wang et al., 2004; Halstead et al., 2005; Halstead et al., 2008a; 
Halstead et al., 2008b). 
Figure legends 
 
Fig.1  
Anti-GD1a antibody is deposited at NoR in a gradient-dependent manner in distal 
intramuscular nerves. TS muscle was treated ex vivo with anti-GD1a antibody 
(100µg/ml for 160mins) and antibody deposits localised and quantified. A) Anti-
GD1a antibody (magenta) binds at the NoR of distal motor axons as determined 
by co-localisation with neurofascin (green) and a narrowing of the endogenously 
expressed axonal CFP (blue). B) Nerve fibres and bundles were categorised by 
size for quantification. Single arrow, single fibre; double arrow, small bundle; 
triple arrow, medium bundle. C) Intensity of anti-GD1a antibody binding was 
assessed according to bundle size; image shows antibody at a single fibre NoR 
compared to that seen at small bundle NoR. D) Single fibres showed significantly 
higher fluorescence intensity at NoR compared to small bundles, small bundles 
compared to medium bundles, and medium bundles compared to large bundles. 
Single fibre, small bundle and large bundles NoR all had significantly increased 
levels compared to control (no antibody) tissue. E) 16hrs following injection of 
anti-GD1a antibody (i.p. total dose 3mg), fluorescence intensity at NoR showed 
the same gradient-dependent binding pattern as that seen in ex vivo antibody 
treated tissue compared to control PBS injected mice. 
* p<0.05, compared to small, medium, large bundles and control; # p<0.05 
compared to medium, large bundles and control; ** p<0.05, compared to large 
bundles and control. Scale bar = 20µm. 
 Fig. 2  
Complement activation at distal nerve NoR is associated with marked attenuation 
of endogenous CFP and loss of perineural currents. Ex vivo TS preparations 
exposed to anti-GD1a antibody or Ringer’s control, followed by 40% NHS as a 
source of complement, were examined for MAC deposition at NoR, the 
distribution of axonal CFP, and perineural current recordings. A) Illustrative 
image of a NoR in a small nerve bundle coated with MAC deposits. B) 
Quantification of MAC deposits demonstrated significantly higher levels at single 
fibre NoR, and small bundle NoR, compared to all other categories. C) Illustrative 
low power images of intramuscular CFP axon bundles (blue) terminating at BTx 
delineated NMJ (magenta) in control tissue exposed to Ringer’s followed by NHS 
(left panel), and anti-GD1a antibody followed by NHS, the latter showing marked 
attenuation (right panel). D) Perineural recordings from control (Ringer’s followed 
by NHS) and treated (anti-GD1a antibody followed by NHS) tissue demonstrate 
intact Na+ (solid arrow) and K+ (broken arrow) currents at nerve terminals, small 
bundles and large bundles in control nerves. These currents are completely 
attenuated in treated nerves, with the exception of the Na+ currents in large 
bundles. 
* p<0.05, compared to small, medium, large bundles and control; # p<0.05 
compared to medium, large bundles and control. Scale bar = 10µm (A) and 20µm 
(C). 
 
Fig. 3  
Immunohistological appearance of nodal markers at the NoR of distal 
intramuscular nerves following exposure to anti-GD1a antibody and NHS 
(treated), compared with Ringer’s and NHS (control). Ex vivo TS muscles were 
incubated with 100µg/ml anti-GD1a antibody and 40% NHS as a source of 
complement. The percentages of NoR positive for immunostaining in each 
bundle category for 5 nodal proteins were determined. A-D) Nav1.6, ankyrin G, 
Caspr and neurofascin immunostaining was significantly reduced at single fibre 
and small bundle NoR after treatment compared to controls. E) Kv1.1 
immunostaining remained unchanged after treatment in all bundle categories.  
Merged illustrations are shown for control tissue; and both single and merged 
illustrations for treated tissue. 
* p<0.05, compared to control counterpart. Scale bar = 10µm.  
 
Fig. 4  
The complement inhibitor, Eculizumab neuroprotects the distal nerve NoR on 
treatment with anti-GD1a antibody and NHS. Eculizumab (100µg/ml) plus 40% 
NHS were admixed 10mins prior to addition to ex vivo TS muscle preparations 
and the protective effects on the immunostaining signal of Nav1.6 channel, 
ankyrin G, Caspr and endogenous axonal CFP were compared to tissue treated 
with anti-GD1a antibody and NHS admixed with the isotype matched control mAb 
ALXN3300. A-C) Nav1.6, ankyrin G and Caspr immunostaining was significantly 
preserved at single fibre and small bundle NoR following Eculizumab treatment; 
illustrative images on right. * p<0.05, compared to control counterpart. Scale bar 
= 10µm. D) Illustrative low power images of intramuscular CFP axon bundles 
(white) in TS muscle terminating at BTx delineated NMJ (magenta) after 
treatment with Eculizumab (left image) or ALXN3300 (right image). The CFP 
signal is completely preserved by Eculizumab, but markedly attenuated with the 
isotype control antibody. Scale bar = 100µm. 
 
Fig. 5  
The calpain inhibitor AK295 protects neurofilament at the nerve terminal from 
degradation by anti-GD1a antibody and NHS exposure. Ex vivo TS muscle was 
treated with anti-GD1a antibody and NHS with or without 100µM AK295.  
Neurofilament immunostaining (red) intensity over the motor endplate (delineated 
by BTx, green) was measured and expressed as a percentage of normal levels. 
In the images, extensive pruning of the distal neurofilament arborisation can be 
seen in AK295 unprotected tissue (right), compared with protected tissue (left). 
* p<0.05, compared to AK295 treatment. Scale bar = 50µm.  
 
Fig. 6 
Calpain inhibition preserves immunostaining profiles of NoR proteins, without 
protecting conduction of distal axons after treatment with anti-GD1a antibody and 
NHS. Ex vivo TS preparations were incubated with anti-GD1a antibody and NHS 
with or without 100µM AK295 and its protective effect on the immunostaining of 
proteins quantified in different bundle categories. Perineural recordings were 
performed after 3h of treatment. A-C) Nav1.6 channel, ankyrin G and Caspr 
immunostaining was significantly preserved by AK295 treatment in single fibres 
and small bundles compared to the same categories in AK295 unprotected 
tissue. Illustrative images depict intact staining to the right of the corresponding 
graphs. D) Perineural current traces show K+ and Na+ ion currents in nerve 
terminals, small bundles and large bundles from completely normal TS tissue 
(control, upper traces) and in tissue treated with anti-GD1a antibody, NHS and 
AK295.  In AK295 treated preparations, no protection of perineural currents in 
single and small bundles is seen. 
* p<0.05, compared to AK295 treatment. Scale bar =10µm. 
 
Fig. 7  
Differential anti-GD1a antibody binding at NoR in phrenic nerve (motor) and sural 
nerve (sensory). Phrenic nerve and sural nerve were desheathed and incubated 
with anti-GD1a antibody (100µg/ml for 2hrs) before the distribution of antibody 
across the NoR was quantitated. A) Illustrative images of staining profile. B) 
There was a significantly greater spread of antibody in phrenic nerve compared 
to sural nerve NoR. C) In sural nerve treated with anti-GD1a antibody plus NHS 
deposits of IgG and MAC were frequently seen at NoR without loss of Nav1.6 
immunostaining, which was very rarely seen in either phrenic nerve or distal 
motor nerve NoR in TS preparations.  
* p<0.05, comapred to phrenic nerve. Scale bar = 5µm. 
 
Fig. 8  
Phrenic nerve NoR immunostaining profiles of nodal proteins after exposure to 
anti-GD1a antibody plus NHS are partially protected by AK295. Phrenic nerve 
was desheathed and treated with anti-GD1a antibody or Ringer’s, plus NHS, with 
and without AK295. and the effect on nodal protein immunostaining was 
quantified. A) Anti-GD1a antibody treated phrenic nerve has significantly less 
NoR that were immuno-positive for Nav1.6 channel, ankyrin G, Caspr, NrCAM 
and moesin than control. B) AK295 does not protect ankyrin G, and only 
modestly protects Nav1.6 channel and Caspr immunostaining from complement-
mediated injury. C) Moesin and NrCAM staining profiles are not significantly 
altered in intensity after anti-GD1a antibody exposure; however they both show 
an abnormal distribution as highlighted in the images. Examples of normal 
control staining of all of the proteins (magenta) versus treated and AK295 
protected nerve. Note occurrence of swollen morphology of treated nerves in DIC 
that is not ameliorated by AK295 treatment. D) Extracellular recordings of anti-
GD1a antibody-treated phrenic nerve show a reduction in CAP amplitudes over 
time that are unaffected by AK295. Anti-GD1a antibody was added for 2 hours; 
subsequently NHS was added for 2 hours starting at 0 mins. Arrows indicate the 
addition of 5µM TTX to terminate the experiment. E) CAP amplitudes are 
expressed as the percentage of the starting value, there being no significant 
difference between AK295 treated or untreated nerves. 
* p<0.05, compared to control or AK295 counterpart. Scale bar = 5µm. 
Supplementary figure legends 
 
Fig. S1  
Ganglioside biosynthesic pathway showing the structure of GD1a and the pattern 
of deficiency seen in GD3 synthase-/- mice. 
 
Fig. S2 
Anti-GD1a antibody more effectively binds nerve terminals in transgenic mice 
over-expressing a-series gangliosides (GD3-/-/CFP) compared to wild type mice, 
as assessed by immunocytochemistry. TS muscle from both modified and WT 
mice were incubated with anti-GD1a antibody (red) and the fluorescence 
intensity of deposits measured over the NMJ, identified by BTx (green). 
* p<0.05, compared to wild-type (WT). Scale bar = 20µm 
 
Fig. S3  
Nerve desheathment results in a significant increase in anti-GD1a antibody 
deposition at NoR. Data shown for phrenic nerve. 
* p<0.05, desheathed nerve compared with intact nerve. 
 
Fig. S4  
GD1a is uniformly present at intramuscular nerve NoR irrespective of bundle 
size. In permeabilised TS preparations, anti-GD1a antibody binds equally to NoR 
in single fibres, small, medium and large bundles, as assessed by 
immunohistology. 
 
Fig. S5  
Three examples of Nav1.6 channel immunostaining at the phrenic nerve NoR 
after anti-GD1a antibody exposure and 30mins treatment with NHS. Various 
stages of dissolution of Nav1.6 immunostaining are evident (arrows), prior to its 
subsequent complete disappearance. 
Scale bar = 5µm 
 
Fig. S6  
Following α-LTx treatment that specifically disintegrates the nerve terminal 
through pore formation in the pre-synaptic membrane, Nav1.6 channel 
immunostaining is unaffected (arrow). * signifies the position of the now invisible 
nerve terminal arborisation where endogenous CFP is lost due to the α-LTx-
evoked injury.  
Scale bar = 20µm. 
 
Fig. S7  
Sciatic nerve and sural nerve CAP recordings show slight or no reduction 
respectively after treatment with anti-GD1a antibody and NHS as a source of 
complement. A) Extracellular recordings were obtained from control and treated 
sciatic nerve and the peak CAP plotted over time. Sciatic nerves were exposed 
to NHS as the complement source prior to transfer to the recording chamber. B) 
For sural nerve, NHS was added to the recording chamber at 0 mins. Arrows 
indicate the addition of 5µM TTX to terminate the experiment. 
 
Fig S8.  
Summary cartoon showing the principal features of the pathophysiological 
casdade occurring at NoR exposed to anti-GD1a antibody and complement. 
MAC pores form in the axolemmal membrane at the NoR that allow sufficient 
uncontrolled ingress of calcium to activate calpain, resulting in degradation of 
calpain substrates including Nav1.6, neurofilament, Caspr and Ankyrin G. 
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